ReviewBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2021
Diabetes and hypertension: Pivotal involvement of purinergic signaling.
Review in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 37 citations in OpenAlex.
- Acute effects of a single electroacupuncture session on purinergic signaling and inflammatory markers in patients with chronic nonspecific low back pain: a pilot study.Purinergic signalling · 2026Article
- MiR-30d-5p Modulates Glucose and Lipid Metabolism by Targeting CD73 through the AMPK Pathway.Cell biochemistry and biophysics · 2025Article
- Identify the co-expressed genes of hypertensive nephropathy and diabetic nephropathy.Scientific reports · 2025Article
- Blackcurrant (Ribes nigrum L.) and Its Association with Donepezil Restore Cognitive Impairment, Suppress Oxidative Stress and Pro-inflammatory Responses, and Improve Purinergic Signaling in a Scopolamine-Induced Amnesia Model in Mice.Neurochemical research · 2025Article
- Pharmacology of P2X Receptors and Their Possible Therapeutic Potential in Obesity and Diabetes.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Correlation between serum adenosine deaminase levels and risk of diabetic foot ulcers in patients with type 2 diabetes mellitus.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2024Article
- Mesenchymal Stem Cells and Purinergic Signaling in Autism Spectrum Disorder: Bridging the Gap between Cell-Based Strategies and Neuro-Immune Modulation.Biomedicines · 2024Review
- Article
- Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.Inflammopharmacology · 2023Review
- Pharmacology of Adenosine Receptors: Recent Advancements.Biomolecules · 2023Review
- Purinergic signaling in thyroid disease.Purinergic signalling · 2023Review
- The real-time detection of acupuncture-induced extracellular ATP mobilization in acupoints and exploration of its role in acupuncture analgesia.Purinergic signalling · 2023Article
- Hyperglycemic conditions induce rapid cell dysfunction-promoting transcriptional alterations in human aortic endothelial cells.Scientific reports · 2022Article
- The purinergic signalling and inflammation in the pathogenesis and progression of diabetes: key factors and therapeutic targets.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- High levels of extracellular ATP lead to different inflammatory responses in COVID-19 patients according to the severity.Journal of molecular medicine (Berlin, Germany) · 2022Article
- Increased levels of serum adenosine deaminase and increased risk of diabetic peripheral neuropathy in type 2 diabetes.Frontiers in endocrinology · 2022Article
- Review
- Targeting purinergic receptors to suppress the cytokine storm induced by SARS-CoV-2 infection in pulmonary tissue.International immunopharmacology · 2021Review
- Effect of β-Caryophyllene on insulin resistance in skeletal muscle of high fat diet and fructose-induced type-2 diabetic rats.Bioinformation · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus (DM) and hypertension are highly prevalent worldwide health problems and frequently associated with severe clinical complications, such as diabetic cardiomyopathy, nephropathy, retinopathy, neuropathy, stroke, and cardiac arrhythmia, among others. Despite all existing research results and reasonable speculations, knowledge about the role of purinergic system in individuals with DM and hypertension remains restricted. Purinergic signaling accounts for a complex network of receptors and extracellular enzymes responsible for the recognition and degradation of extracellular nucleotides and adenosine. The main components of this system that will be presented in this review are: P1 and P2 receptors and the enzymatic cascade composed by CD39 (NTPDase; with ATP and ADP as a substrate), CD73 (5'-nucleotidase; with AMP as a substrate), and adenosine deaminase (ADA; with adenosine as a substrate). The purinergic system has recently emerged as a central player in several physiopathological conditions, particularly those linked to inflammatory responses such as diabetes and hypertension. Therefore, the present review focuses on changes in both purinergic P1 and P2 receptor expression as well as the activities of CD39, CD73, and ADA in diabetes and hypertension conditions. It can be postulated that the manipulation of the purinergic axis at different levels can prevent or exacerbate the insurgency and evolution of diabetes and hypertension working as a compensatory mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.